Closed PAR-25-300 CFDA 93.855 Discretionary

Targeting Cell Surface HIV Envelope for Cell Elimination (R01 Clinical Trial Not Allowed)

Posted by National Institutes of Health

Opportunity snapshot. This Grants.gov announcement — Targeting Cell Surface HIV Envelope for Cell Elimination (R01 Clinical Trial Not Allowed) — is cataloged under number PAR-25-300 and tied to CFDA assistance listing 93.855, posted by National Institutes of Health. Grants.gov currently shows the opportunity as closed, first posted on December 2, 2024 and last updated on February 19, 2026. The funding category is Discretionary, delivered as a grant.

Award economics. The award range on file is Varies by applicant. Cost sharing is not required, so applicants do not need to commit matching funds to be competitive on this opportunity. Federal award ranges are often upper bounds; actual allocations reflect program appropriations, the strength of the applicant pool, and the evaluation committee's scoring.

Deadline and action path. This opportunity closed on February 19, 2026. Future funding cycles may be published under the same CFDA number, so monitoring the parent program page is the most reliable way to catch re-announcements. Every Grants.gov submission requires an active SAM.gov registration and a Unique Entity ID. Review the Eligibility section below carefully — federal eligibility categories (nonprofit, state or local government, tribal, individual, educational institution, small business) have distinct registration and reporting requirements. Pre-application outreach to the listed agency contact is permitted and often welcomed — it helps clarify scope and scoring priorities.

Award Range

Varies by applicant

Close Date

February 19, 2026

Posted

December 2, 2024

Instrument

Grant

Description

The purpose of this notice of funding opportunity (NOFO) is to support the investigation of HIV-1 Envelope (Env) cell surface expression, the structural mechanism of biologic-mediated cell killing, and the development of novel approaches to enhance the recognition and elimination of Env-expressing, HIV-1 infected cells. These studies are expected to inform the development of immunotherapies and targeted vaccines for HIV-1 prevention and cure.

Eligibility

00;01;02;04;05;06;07;08;11;12;13;20;22;23;25

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Agency Contact

NIH Grants Information <br/>grantsinfo@nih.gov

Key Dates

Posted December 2, 2024
Close Date February 19, 2026
Archive Date March 21, 2026
Last Updated February 19, 2026

Frequently Asked Questions

What is this grant opportunity?
This is a federal funding opportunity titled "Targeting Cell Surface HIV Envelope for Cell Elimination (R01 Clinical Trial Not Allowed)", offered by National Institutes of Health. It is associated with CFDA program 93.855. The purpose of this notice of funding opportunity (NOFO) is to support the investigation of HIV-1 Envelope (Env) cell surface expression, the structural mechanism of biologic-mediated cell killing, an...
Is this opportunity still open?
No, this opportunity is closed. It closed on February 19, 2026. Check the parent program page for future funding cycles.
How much funding is available?
The award range for this opportunity is Varies by applicant.
How do I apply?
Applications for federal grant opportunities are typically submitted through Grants.gov. Visit the official listing at grants.gov for application instructions, required documents, and submission deadlines.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainGrants Editorial